logo
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements

Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements

Business Wire24-04-2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, 'Median' or 'The Company'), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its Q1 2025 key financial indicators (unaudited) and provides an update on Q1 operational achievements.
Fredrik Brag, CEO and Founder of Median Technologies, commented: 'The past quarter has seen the successful culmination of a transformational period for the Company: we are beginning to see the benefits of ongoing operational optimization in our iCRO business unit, and have recorded a €74.8 million all-time high order backlog. At the same time, after having met all the key endpoints in pivotal studies, RELIVE and REALITY, our lead Software as a Medical Device for lung cancer screening, eyonis™ LCS, has completed clinical development and is entering regulatory registration phase, the final step before commercialization. We expect our game-changing AI-driven SaMD will afford medical professionals' greater efficiency in lung cancer screening – while improving accuracy – to save many lives. Our timing is perfect as the U.S. and the rest of the world are moving now to increase the number of lifesaving lung cancer screenings performed each year. The math is simple, healthcare systems that increase screening capacity, will catch lung cancer early, when it can still be cured; and this will benefit not only the patients we serve but also avoid the tremendous costs of late-stage lung cancer treatment.'
eyonis™ LCS SaMD: AI-driven innovation for Lung Cancer Screening
Q1 2025 key achievements
On March 31, 2025, the Company announced the successful completion of RELIVE, the second pivotal study of eyonis™ LCS, Median's AI-driven Software as a Medical Device (SaMD) for computer aided detection and diagnosis (CADe/CADx) of lung cancer. RELIVE final results confirmed the safety and efficacy of eyonis™ LCS SaMD, successfully completing the studies required to achieve marketing authorizations in the US and Europe.
In addition, this March, Median Technologies successfully achieved ISO/IEC 27001:2022 and HDS V2.0 certifications for eyonis™ activities, highlighting the Company's commitment to best practices in information security, including Personal Health Information. The notoriously difficult to obtain ISO 27001:2022 certification (international) and HDS V2.0 certification (France) are key to successful marketing of Median's eyonis™ suite of SaMDs in the US, in Europe and worldwide. The certifications were granted following a rigorous independent audit.
ISO/IEC 27001 is the international standard for information security management and sets out a framework for all organizations to establish, implement, operate, monitor, review, maintain and continually improve an Information Security Management System (ISMS). HDS (Hébergeurs de Données de Santé / Health Data Hosting) certification is strongly based on ISO/IEC 27001 requirements and is required for entities that host the personal health data governed by French laws and collected for delivering health services.
Upcoming key milestones
eyonis™ LCS' regulatory filings for U.S. FDA 510(k) clearance and CE marking, will be submitted in May and June, respectively. Consequently, given normal review times, Median continues to expect eyonis™ LCS' FDA 510(k) clearance in Q3 2025 and CE marking in Q1 2026, as previously communicated.
Median eyonis™ teams are preparing for eyonis™ LCS commercial launch in the US, shortly after FDA clearance, around the end of 2025.
iCRO: Q1 2025 revenue at €6.0 million confirming return to revenue growth, order backlog at an all-time high of €74.8 million
Median revenue during the period stemmed entirely from the iCRO Business Unit, which provides imaging services to measure drug efficacy in industry-sponsored oncology trials.
Q1 2025 revenue totaled €6.0 million, up 11%, compared to €5.4 million revenue during the same period in 2024, building on the revenue growth acceleration seen during the second half of 2024.
On March 31, 2025, the order backlog 1 hit its highest level ever reached at €74.8 million, vs €71.0 million as of December 31, 2024, i.e., a 5.4% increase primarily driven by new awards and contracts from the undisclosed Top 3 pharma company, to which Median became preferred vendor in May 2024.
Cash and cash equivalents as of March 31, 2025
On March 31, 2025, cash and cash equivalents stood at €8.8 million, versus €8.1 million on December 31, 2024. In Q1 2025, the Company's cash position was strengthened with the receipt of €4 million from the first tranche of the equity line completed with IRIS and announced in January 2025 and with the advanced payment of the 2024 French research and innovation tax credit for an amount of €1.4 million.
Median and the European Investment Bank (EIB) have extended the maturity of the loan granted in 2020 by six months, i.e., until October 2025. Furthermore, as previously announced, and communicated on the EIB website, the Company is working with the European Investment Bank on finalizing in the coming weeks, an agreement for a new financing facility of up to €37.5 million to enable the regulatory and commercialization activities of eyonis™ LCS. Upon completion of the agreement, which would trigger the drawdown of a first tranche, the Company estimates that it will be able to cover its financing needs until Q4 2025.
Subsequent tranches of the above-mentioned EIB financing facility will be made available upon completion of certain undisclosed milestones. Fulfillment of these milestones, enabling further drawdowns, should contribute to extending the Company's cash runway until at least the end of 2026.
Next financial release on April 29, 2025, after the market closing:
2024 Financial Report
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.
These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time22 minutes ago

  • Business Wire

Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VESTIS CORPORATION (VSTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2025, Vestis released its second quarter fiscal 2025 financial results and revised its prior growth and revenue guidance for 2025, providing guidance for the third quarter, falling significantly below market expectations. The Company explained that the poor results were partially due to 'lost business in excess of new business' but primarily on 'lower adds over stops, which is how [it] describe[s] volumes changes with [its] existing customers.' On this news, Vestis's stock price fell $3.27, or 37.5%, to close at $5.44 per share on May 7, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Vestis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire

time29 minutes ago

  • Business Wire

Sable Offshore Corp. (SOC) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sable Offshore Corp. ('Sable' or the 'Company') (NYSE: SOC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SABLE OFFSHORE CORP. (SOC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 19, 2025, Sable announced that it had resumed oil production from one of three offshore platforms related for its Las Flores pipelines ('Onshore Pipeline') in California. Then, on May 23, 2025, the California State Land Commission sent Sable a letter regarding its May 19th announcement, warning that it 'appears to mischaracterize the nature of recent activities, causing significant public confusion and raising questions regarding Sable's intentions,' and that Sable had conflated offshore well testing activities required by a federal regulatory agency with the restart of operations. Then, on May 28, 2025, the Santa Barbara County Superior Court approved a preliminary injunction from the California Coastal Commission regarding Sable's maintenance and repair work in the coastal zone related to the Onshore Pipeline. On this news, Sable's stock price fell $5.04, or 15.3%, to close at $27.89 per share on May 28, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Sable securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust
KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust

Business Wire

time33 minutes ago

  • Business Wire

KBRA Assigns Preliminary Ratings to CROSS 2025-H5 Mortgage Trust

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to ten classes of mortgage pass-through certificates from CROSS 2025-H5 Mortgage Trust, an RMBS transaction issued under the CROSS shelf, where Hildene in affiliation with CrossCountry Mortgage and CrossCountry Capital sponsored the transaction. The $416.5 million transaction is collateralized by a pool of 881 residential mortgages originated by CCM, including a meaningful concentration of collateral that KBRA considers to be 'non-prime', with fixed-rate mortgages (FRMs) and hybrid adjustable-rate mortgages (ARMs) making up 86.7% and 13.3% of the pool, respectively. KBRA's rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction's payment structure, reviews of key transaction parties and an assessment of the transaction's legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology. To access ratings and relevant documents, click here. Click here to view the report. Recent Publications Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009870

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store